Medical Therapy. Efficacy or Lack of Efficacy

Administering Nitric Oxide (NO) with High Flow Nasal Cannulas: A Simple Method

Vladimir L. Cousin, Raphael Joye, Angelo PolitoUniversity of Geneva. Switzerland Advances in Respiratory MedicineAdv Respir Med 2024; 92(1):92-95DOI: 10.3390/arm92010012 AbstractInhaled nitric oxide (iNO) is a pulmonary vasodilator that plays an important clinical ICU role. The administration of iNO is usually performed through an endotracheal tube, but spontaneously breathing patients might also benefit from iNO administration. The […]

Administering Nitric Oxide (NO) with High Flow Nasal Cannulas: A Simple Method Read More »

Continuous Positive Airway Pressure in the Treatment of Pediatric High Altitude Pulmonary Edema: A Case Study

Ryan Hodnick, Michael L. Cohen, Joseph B. Loehner, Jennifer MazzantiTrans Aero Medevac. TriState CareFlight.United States Wilderness and Environmental MedicineWilderness Environ Med 2024; DOI: 10.1177/10806032231222003 AbstractTreatment of high altitude pulmonary edema (HAPE) can be challenging and is further complicated in the pediatric patient in the prehospital environment. The following case presents a decompensating pediatric patient with HAPE in the prehospital

Continuous Positive Airway Pressure in the Treatment of Pediatric High Altitude Pulmonary Edema: A Case Study Read More »

Therapy in pediatric pulmonary hypertension: memoire of an unfinished journey

Martin Hosking, Angela BatesUniversity of British Columbia. University of Alberta.Canada Canadian Journal of CardiologyCan J Cardiol 2024;DOI: 10.1016/j.cjca.2024.02.009 AbstractAbstract Not Available CategoryMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed Publication: Filed (PHiled). Greater than 1-2 years since publication Article AccessFree PDF File or Full Text Article Available Through

Therapy in pediatric pulmonary hypertension: memoire of an unfinished journey Read More »

Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study

Dunbar Ivy, Maurice Beghetti, Ernesto Juaneda‑Simian, Ramiya Ravindranath, Mary Ann Lukas, Sandra Machlitt‑Northen, Nicola Scott, Jun Narita, Rolf M. F. BergerChildren’s Hospital Colorado. University Children’s Hospital HUG and University of Geneva. Hospital de Niños de la Santísma Trinidad. Glaxo-Smith-Kline. Osaka University Graduate School of Medicine. Beatrix Children’s Hospital, University Medical Center Groningen and University of

Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study Read More »

[Risks of magistral preparations in pediatrics]

Charlotte Rosen, Caroline Jacqmart, Corinne Charlier, Maurice Beghetti, Marie-Christine SeghayeCentre Hospitalier Universitaire de Liège. Hôpitaux universitaires de Genève.Belgium and Switzerland Revue Medicale de LiegeRev Med Liege 2024; 79: 104-109DOI: Not Available AbstractVasoreactive pulmonary arterial hypertension (PAH) in children is a form of idiopathic PAH that responds to vasoreactive testing with nitric oxide (NO) by a

[Risks of magistral preparations in pediatrics] Read More »

Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia

Shino Yoshida, Olivia Eichelberger, Michael Ulis, Alexander M. Kreger, George K. Gittes, Joseph T. ChurchUniversity of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh. University of Michigan Medical School.United States Pediatric SurgeryPediatr Surg 2024;DOI: 10.1016/j.jpedsurg.2024.01.010 AbstractBackground: Pulmonary hypertension remains difficult to manage in congenital diaphragmatic hernia (CDH). Prenatal therapy may ameliorate postnatal pulmonary hypertension. We

Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia Read More »

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension

Justin J. Kochanski, Jeffrey A. Feinstein, Michelle Ogawa, Victor Ritter, Rachel K. Hopper, Gregory T. AdamsonStanford University School of Medicine.United States Pulmonary CirculationPulm Circ 2024; DOI: 10.1002/pul2.12328 AbstractChildren with severe Group 1 pulmonary arterial hypertension (PAH) have an unpredictable response to subcutaneous treprostinil (TRE) therapy, which may be influenced by age, disease severity, or other unknown

Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension Read More »

Successful treatment of pulmonary arterial hypertension in a 2-month-old female infant with incontinentia pigmenti: A case report

Marta Marcia, Paola Coppo, Giuseppe Alberto Annoni, Gaetana Ferraro, Gabriella Agnoletti, Giuseppe Antonio MazzaCity of Health and Science Hospital.Italy Annals of Pediatric CardiologyAnn Pediatr Cardiol 2023; 16: 297-300DOI: 10.4103/apc.apc_75_23 AbstractIncontinentia pigmenti (IP) is a rare X-linked dominant neuroectodermal dysplasia affecting almost exclusively females. It is caused by loss-of-function mutations in the inhibitor of kappa light polypeptide

Successful treatment of pulmonary arterial hypertension in a 2-month-old female infant with incontinentia pigmenti: A case report Read More »

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension

Michael W. Cookson, John P. KinsellaUniversity of Colorado Anschutz School of Medicine and Children’s Hospital Colorado.United States Clinics in PerinatologyClin Perinatol 2024; 51: 95-111DOI: 10.1016/j.clp.2023.11.001 AbstractPivotal trials investigating the use of inhaled nitric oxide (iNO) in the 1990s led to approval by the Food and Drug Administration in 1999. Inhaled nitric oxide is the only approved

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension Read More »

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach

Satyan Lakshminrusimha, Steven H. AbmanUniversity of California, Davis Children’s Hospital. University of Colorado Anschutz Medical Campus.United States Clinics in PerinatologyClin Perinatol 2024; 51: 77-94DOI: 10.1016/j.clp.2023.12.003 AbstractOxygen is a specific pulmonary vasodilator. Hypoxemia causes pulmonary vasoconstriction, and normoxia leads to pulmonary vasodilation. However, hyperoxia does not enhance pulmonary vasodilation but causes oxidative stress. There are no clinical

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach Read More »

Scroll to Top